Updates from Bactiguard
Here you’ll find the latest news and insights from Bactiguard.
During 2025, we built a stronger foundation by sharpening our focus as a licensing company, strengthening existing partnerships, and solidifying our therapeutic...
A year of strategic execution concluded with a strong Q4 Fourth quarter 2025 (October – December) Total revenue amounted to SEK 65.6...
Continued profitability and clinical evidence supporting future growth Third quarter 2025 (July – September) Total revenue amounted to SEK 48.4 (73.9) million,...
Cleaning is one of the most critical and often overlooked steps in wound management. This was the central message when Wound Management...
Positive EBITDA momentum carried forward in Q2 Second quarter 2025 (April – June) Total revenue amounted to SEK 1 (60.9) million, a...
In 2024, Bactiguard completed the strategic shift needed to enable the company to be the premier choice for both current and future...
Recently, Bactiguard’s Chief Medical Officer, Pankaj Malhotra, and Sophie Dahan, General Manager of Licensing, attended the European Bone and Joint Infection Society...
Bactiguard joined license partner BD at leading healthcare conference in India, CRITICARE 2025. With healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) posing...
On 22 November, we hosted our annual Global Wound Management Webinar, broadcast live from London. With over 300 participants tuning in from...
From 18th to 20th October 2024, Wound Management by Bactiguard participated at the IWII & 6th Global Wound Conference in Selangor, Malaysia,...
As part of the collaboration with license partner Zimmer Biomet, Bactiguard had the opportunity to participate in the 50th Annual Meeting of...
Bactiguard recently participated in the EFORT Congress 2024, held in Hamburg, Germany. EFORT, the European Federation of National Associations of Orthopedics and...